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AbstrAct
Objective To evaluate the impact of an integrated 
diabetes and kidney disease model of care on health- 
related quality of life (HRQOL) of patients with comorbid 
diabetes and chronic kidney disease (CKD).
Research design and methods A longitudinal study of 
adult patients (over 18 years) with comorbid diabetes and 
CKD (stage 3a or worse) who attended a new diabetes 
kidney disease service was conducted at a tertiary 
hospital. A questionnaire consisting of demographics, 
clinical data, and the Kidney Disease Quality of Life 
(KDQOL-36) was administered at baseline and after 12 
months. Paired t- tests were used to compare baseline 
and 12- month scores. A subgroup analysis examined the 
effects by patient gender. Multiple regression analysis 
examined the factors associated with changes in scores.
Results 179 patients, 36% of whom were female, with 
baseline mean±SD age of 65.9±11.3 years, were studied. 
Across all subscales, HRQOL did not significantly change 
over time (p value for all mean differences >0.05). 
However, on subgroup analysis, symptom problem list and 
physical composite summary scores increased among 
women (MD=9.0, 95% CI 1.25 to 16.67; p=0.02 and 
MD=4.5, 95% CI 0.57 to 8.42; p=0.03 respectively) 
and physical composite scores decreased among men 
(MD=−3.35, 95% CI −6.26 to −0.44; p=0.03).
Conclusion The HRQOL of patients with comorbid 
diabetes and CKD attending a new codesigned, integrated 
diabetes and kidney disease model of care was maintained 
over 12 months. Given that HRQOL is known to deteriorate 
over time in this high- risk population, the impact of 
these findings on clinical outcomes warrants further 
investigation.
InTROduCTIOn
Diabetes has become a major challenge to 
healthcare delivery in the 21st century1 and 
data from economic modeling suggest a 
substantial increase in global health expendi-
ture attributable to diabetes care.2 The global 
prevalence of diabetes is expected to rise to 
592 million cases by 2035 up from 415 million 
cases of diabetes reported in 2015.3 This 
increase in the number of people with 
diabetes has led to an upsurge in the number 
of patients with chronic kidney disease (CKD) 
and those commencing renal replacement 
therapy (RRT), in combination with an 
overall trend of earlier commencement of 
dialysis.4 The accelerating growth in patients 
with comorbid diabetes and CKD requiring 
significance of this study
What is already known about this subject?
 ► Among patients with chronic kidney disease (CKD), 
health- related quality of life (HRQOL) gradually de-
clines as the disease progresses with the worst 
scores reported by those with advanced renal 
disease.
 ► When CKD coexists with diabetes, a marked deterio-
ration in HRQOL is expected.
What are the new findings?
 ► HRQOL was preserved over 12 months among those 
attending a codesigned integrated diabetes and kid-
ney disease model of care.
 ► When women and men were considered separately, 
the symptom problem list and physical composite 
scores significantly improved among women while 
the physical composite score slightly deteriorated 
among men.
How might these results change the focus of 
research or clinical practice?
 ► Person- centered integrated clinics for patients with 
diabetes and renal dysfunction are a promising 
approach for improving patient outcomes such as 
HRQOL.
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RRT and the associated health and resource implications 
highlight the need for new directions in managing this 
high- risk population.
The management of patients with comorbid diabetes 
and CKD is complex and requires considerable coordina-
tion and facilitation of care during the disease continuum. 
Integrated person- centered diabetes and kidney disease 
clinics have emerged as a promising approach to the 
management of patients with comorbid diabetes and 
CKD.5 These clinics reduce the unnecessary burden of 
multiple appointments for patients who already have 
multiple comorbidities. Patients attending these clinics 
also have input from a multidisciplinary team including 
endocrinologists, nephrologists, nurse educators and 
dietitians.6 7 Additionally, some combined diabetes and 
kidney disease specialty clinics have reported improve-
ments in metabolic and blood pressure control,5 7 a 
reduction in progression of renal disease8 and outpa-
tient cost savings.9 However, previous studies have not 
reported the effects on patient- reported outcomes such 
as health- related quality of life (HRQOL).
Among patients with CKD, HRQOL gradually declines 
as the disease progresses10 with the worst scores reported 
by those with advanced renal disease.11 When CKD coex-
ists with diabetes, a marked deterioration in HRQOL is 
expected.12 The objective of this study was to evaluate 
the impact of an integrated diabetes and kidney disease 
model of care13 on HRQOL of patients with comorbid 
diabetes and CKD.
MeTHOds
study design and population
This was a longitudinal study with a follow- up period of 
12 months for adult patients (over 18 years) with diabetes 
and CKD who were referred to the Diabetes Kidney 
Service (DKS)13 at Monash Health between January 
2015 and August 2017. The diagnosis of diabetes was 
noted in medical records and/or confirmed by labo-
ratory results as per the World Health Organisation 
(WHO) criteria.14 15 Patients were considered to have 
CKD if they had a sustained estimated glomerular filtra-
tion rate (eGFR) <60 mL/min/1.73 m2 calculated using 
the Chronic Kidney Disease Epidemiology Collabora-
tion equation16 (ie, two or more eGFR readings) over a 
3- month period. Patients were excluded if they had an 
eGFR ≥60 mL/min/1.73 m2 since this may reflect normal 
physiologic age- related changes in kidney function. The 
reporting in this study followed the Strengthening the 
Reporting of Observational Studies in Epidemiology 
guidelines.17
The diabetes and kidney disease model of care
The diabetes and kidney disease model of care used by 
the DKS has been described in detail before.13 In brief, 
this model of care was codesigned by general practi-
tioners (GP), endocrinologists, nephrologists, nurse 
practitioners, patients with diabetes and CKD and patient 
advocacy groups such as Diabetes Australia and Kidney 
Health Australia in 2015. The design was informed by 
findings from a large multisite formative evaluation of 
the barriers and enablers of current health services for 
diabetes and CKD, and the needs of patients, carers, and 
their health professionals.18
The diabetes and kidney disease model of care 
provides patient- centered, coordinated multidisciplinary 
assessment and management of patients with comorbid 
diabetes and CKD in partnership with primary care. This 
service is designed to improve patient self- management 
and improve communication and coordination of care 
between endocrinologists, nephrologists and GPs, who 
remain the coordinator of patient care. As a new initia-
tive, the service also provides a liaison service/GP phone 
advice hotline to discuss referrals and patient queries 
during office hours (09:00 to 17:00 hours) and educa-
tion on managing diabetes and CKD. The team includes 
a consultant endocrinologist and nephrologist, specialist 
registrars in endocrinology and nephrology, diabetes 
and renal nurse practitioners, dietitian, administration 
and a research officer (for continual service evaluation 
and improvement). Consistency is maintained by using 
standard patient assessment templates and minimizing 
staff attrition. Fidelity assessment is performed monthly 
to ensure that all aspects of the clinic run as per design. 
Criteria for referral to the integrated clinic include type 
1 or type 2 diabetes with an eGFR <60 mL/min/1.73 m2.
Measures
Demographic and clinical variables
Age, gender, ethnicity, alcohol and smoking history, 
stage of kidney disease, duration of kidney disease and 
duration of diabetes were obtained from the first ques-
tionnaire (online supplementary appendix 1) which was 
prospectively completed by site study staff or the clini-
cian, using standardized procedures from the doctor’s 
notes and laboratory results from the clinic.
Socioeconomic status (SES) was estimated using the 
Australian Bureau of Statistics data. Postcodes were coded 
according to the Index of Relative Social Disadvantage 
(IRSD), a composite measure based on selected census 
variables, which include income, educational attainment 
and employment status. The IRSD scores for each post-
code were then grouped into quintiles. The first quintile 
had individuals from the most disadvantaged areas and 
the fifth quintile comprised individuals from the least 
disadvantaged areas.19
Health-related quality of life
HRQOL was assessed using the English version of the 
Kidney Disease Quality of Life (KDQOL-36) question-
naire. The KDQOL-36 comprises two composite scores 
for physical and mental health with a population mean 
of 50 (SD=10) and three kidney disease- specific scales. 
The three kidney disease- specific scales are the burden 
of kidney disease, symptom/problems list and the effects 
of kidney disease subscales20 (online supplementary 
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Figure 1 Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) flow diagram of included 
patients. eGFR, estimated glomerular filtration rate.




Age groups   
  <67 years 81 (45)
  ≥67 years 98 (55)
Age by gender (years)   
  Female 68.6±9.8
  Male 64.3±11.8
Gender (female) 65 (36)
Country of birth   
  Australia 42 (23.6)
  Sri Lanka 20 (11.2)
  Mauritius 11 (6.2)
  Samoa 9 (5.1)
  India 9 (5.1)
  England 8 (4.5)
  Fiji 8 (4.5)
  Italy 6 (3.4)
  Vietnam 6 (3.4)
  New Zealand 5 (2.8)
  Others 55 (30.7)
Socioeconomic status   
  Upper 9 (5.0)
  Upper middle 32 (17.9)
  Lower middle 54 (30.2)
  Upper lower 11 (6.2)
  Lower 73 (40.8)
Smoking, current 6 (3.4)
Alcohol, current use 53 (33.5)
Diabetes   
  Type 1 6 (3.4)
  Type 2 173 (96.6)
  Duration (years) 16.4±8.6
  Glycated hemoglobin (%) 8.1±1.6
Chronic kidney disease   
  Stage 3a 36 (20.1)
  Stage 3b 75 (41.9)
  Stage 4 38 (21.2)
  Stage 5 30 (16.8)
  Dialysis, current 21 (11.9)
appendix 2). Item scores were summed for each scale and 
transformed on a scale of 0–100 with a higher score indi-
cating better HRQOL. The scores of the two summary 
measures and the total 36- Item Short Form Health Survey 
(SF-36) are based on the average of the respective scale 
components.
statistical analysis
First, participants with missing values in the KDQOL 
measure (that did not allow for calculation of the 
subscales) were excluded following the recommendations 
of the instrument’s developers.21 Second, means and SDs 
for all HRQOL subscales were calculated for baseline and 
follow- up scores. Change scores were calculated as the 
difference between follow- up and baseline scores. Dete-
riorations in HRQOL were denoted by a negative value 
in change scores while a positive value denoted improve-
ments. Third, we compared baseline and follow- up scores 
of the HRQOL subscales by paired sample t- tests. Lastly, we 
performed multiple regression analyses using the change 
scores as dependent variables to determine the factors 
associated with the change scores. Potential predictor vari-
ables for change in HRQOL scores were age, gender, stage 
of kidney, duration of diabetes and SES which we have 
described previously.22 To determine whether changes in 
scores were clinically meaningful, we used the guidelines 
set by the developers of the SF-36, which suggest that a 5–10 
point change along any of the instrument’s subscales is clin-
ically meaningful.23 In our analysis, we defined clinically 
meaningful results as a 5- point difference in scores from 
baseline to 12 months. CIs were reported at the 95% level 
and results were considered significant at conventional 
p<0.05 level. All analyses were performed with Stata V.15.0 
(StataCorp, College Station, TX).
ResulTs
Participants
Of a total of 393 patients screened, 290 entered the study. 
During follow- up, 11 died (before the 12- month visit) 
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Figure 2 Socioeconomic status in quintiles. The first 
quintile had individuals from the most disadvantaged areas 
and the fifth quintile comprised individuals from the least 
disadvantaged areas.
Table 2 Change in health- related quality of life scores for all patients (n=179)
Scale (range, 0–100) Baseline Follow- up Change scores (95% CI) P value*
Symptom problem list 72.5±20.5 74.3±20.1 1.7 (−2.6 to 6.0) 0.43
Effect of kidney disease 74.4±23.4 73.2±23.8 −1.2 (−6.5 to 4.2) 0.67
Burden of kidney disease 59.2±30.8 57.1±32.3 −2.1 (−9.3 to 5.0) 0.56
Physical composite summary 35.5±10.6 35.1±11.1 −0.4 (−2.8 to 2.0) 0.73
Mental composite summary 48.3±10.5 46.8±11.2 −1.5 (−3.9 to 1.0) 0.24
*P value from Student’s t- test.
and 179 (64%) completed the 12- month questionnaires 
(figure 1). The baseline demographic and clinical char-
acteristics of the study population are shown in table 1. 
Thirty- six percent of the participants were women. At 
baseline, the mean (SD) age for all participants was 
65.9±11.3 years and 64.3±11.8 and 68.6±9.8 years for men 
and women, respectively. Participants came from various 
racial and ethnic groups with only 24% having been born 
in Australia. Forty percent of the participants lived in 
the most disadvantaged areas (quintile 1) (figure 2). All 
had diabetes with most having type 2 diabetes (97%) and 
moderate to advanced CKD (83% stage 3–4 CKD). For all 
patients, mean subscale scores at baseline were 72.5±20.5, 
74.4±23.4, 59.2±30.8, 35.5±10.6 and 48.3±10.5 for the 
symptom problem list, effect of kidney disease, burden 
of kidney disease, physical composite summary and 
mental composite summary scales, respectively (table 2). 
Patients who did not complete the 12- month follow- up 
were comparable to patients who did with respect to age, 
gender, duration of diabetes, type of diabetes and stage 
of CKD (online supplementary table S1).
Changes of HRQOl scores from baseline to follow-up
Across all subscales, HRQOL did not significantly change 
over time (p value for all mean differences >0.05 and all 
change scores less than 5 points) (table 2). However, 
on subgroup analysis, symptom problem list and phys-
ical composite summary scores increased for women 
(MD=9.0, 95% CI 1.25 to 16.67, p=0.02 and MD=4.5, 
95% CI 0.57 to 8.42, p=0.03 respectively) and physical 
composite scores decreased for men (MD=−3.35, 95% CI 
−6.26 to −0.44; p=0.03) (table 3).
Factors associated with change scores
The changes in the symptom problem list and physical 
composite summary scores were 11 and 8 points (p<0.05) 
greater in women than in men (table 4). The changes in 
the effect of kidney disease, burden of kidney disease and 
mental composite score for patients with stage 5 kidney 
disease were 21, 38 and 9 points (p<0.05) greater than for 
patients with mild kidney disease, respectively (table 4).
In men, the changes in the symptom problem list and 
effect of kidney disease scores in those with stage 5 kidney 
disease were 48 and 44 points (p<0.05) greater than in 
those with mild kidney disease (online supplementary 
table S2). In women, the symptom problem list change 
score for those aged 67 years or older was on average 
12 points less (p<0.05) than for those aged less than 67 
years. In addition, women with stage 5 kidney disease had 
greater changes in the burden of kidney disease scores 
(39 points; p<0.05) than women with mild kidney disease 
(online supplementary table S3).
dIsCussIOn
In this longitudinal study of patients with comorbid 
diabetes and CKD, we have shown that HRQOL was 
preserved over 12 months among those attending a code-
signed integrated diabetes and kidney disease model 
of care. Scores across all the subscales of the KDQOL 
instrument were similar at entry into the new service and 
at 12 months’ follow- up. When women and men were 
considered separately, the symptom problem list and 
physical composite scores significantly improved among 
women while the physical composite score slightly deteri-
orated among men. Among all patients, those with stage 
5 kidney disease experienced a greater improvement in 
scores for the effect of kidney disease, burden of kidney 
disease and mental composite summary scores than those 
with mild kidney disease.
Several studies of patients with CKD have reported 
that HRQOL significantly deteriorates over time24 25 with 
the major predictors of the decline being a reduction in 
eGFR, age and other comorbidities.26 Notably, in studies 
of patients with comorbid diabetes and CKD, HRQOL 
deteriorated at a faster rate than in patients with CKD 













































































































































































































































































































































































































































alone.24 Our longitudinal study has found that a code-
signed integrated diabetes and kidney disease model 
of care may prevent deterioration of HRQOL among 
patients with comorbid diabetes and CKD especially 
among those with stage 5 CKD. Reasons for this may 
be that the integrated service provides patient- centered 
care, higher quality of care, appropriate patient referrals 
and greater convenience for the patient which when put 
together, maintain HRQOL. However, the impact of the 
integrated service on HRQOL may have been influenced 
by response shift, a phenomenon which occurs when 
patients change their values and the conceptualization of 
quality of life over time.27
Cross- sectional studies among patients with comorbid 
diabetes and CKD22 28 have previously reported that 
women have lower HRQOL scores compared with men 
especially in the physical composite score. In our study, 
we had expected the physical composite scores for 
both men and women to decline over time as reported 
previously.29 However, the physical composite scores for 
women remained stable while those for men declined 
minimally. This suggests that women may have been 
more amenable to the interventions embedded within 
the integrated service than men. To optimize the bene-
fits of the integrated service to men, peer support- based 
interventions may need to be provided.30
Our data demonstrate that an integrated clinic espe-
cially improved HRQOL in patients with advanced kidney 
disease who are known to have very low quality of life.25 
Patients with stage 5 kidney disease experienced a greater 
change in scores for the effect of kidney disease, burden 
of kidney disease and mental composite summary scores 
than those with mild kidney disease. A reason for this is 
that those with advanced kidney disease may have better 
accepted their diagnosis31 and been ready to embrace 
interventions embedded within the integrated clinic to 
improve their HRQOL. Another reason is that patients 
with advanced kidney disease may get more attention 
from clinicians compared with patients with mild kidney 
disease leading to improved quality of life in particular 
subscales as seen in this study. This especially applies to 
those on or commencing dialysis where frequent interac-
tions with nursing and medical staff is the norm. Addition-
ally, an improvement in quality of life may be perceived 
differently by patients with advanced kidney disease and 
those with mild kidney disease. A slight improvement in 
quality of life for patients with stage 5 kidney disease may 
have a greater influence on how they feel than in patients 
with mild kidney disease. We did not expect patients with 
advanced kidney disease to have clinically significant 
change scores in the physical composite scale compared 
with those with mild kidney disease due to the physical 
limitations associated with comorbid diabetes and CKD.
Findings in this longitudinal study have important 
implications for practice and future research. First, the 
determinants of HRQOL in patients with comorbid 
diabetes and CKD are clearer and most importantly, 
HRQOL may be improved or preserved by interventions 
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codesigned by patients and health professionals. Second, 
HRQOL should be routinely measured in patients with 
comorbid diabetes and CKD to enable the provision of 
tailored interventions. Currently, HRQOL measurement 
in patients with comorbid diabetes and CKD remains 
largely a research endeavor, although monitoring 
HRQOL in routine clinical care has been shown to be 
feasible.32
Our findings should be interpreted in light of the 
strengths and limitations of our study design. The 
strengths include the use of a study design that allowed us 
to evaluate the impact of codesigned integrated diabetes 
and kidney disease model of care on HRQOL of patients 
with comorbid diabetes and CKD over time. Additionally, 
our participants were drawn from a diverse population 
allowing for generalizability of study findings. Lastly, there 
were no differences between patients who completed the 
study and those who were lost to follow- up. The limita-
tions include that two measurement points may provide 
less stable results compared with multiple data collection 
points. However, we chose not to survey patients more 
frequently to avoid bias associated with repeated testing. 
Furthermore, patients were followed up for a period of 
12 months which may not be enough to realize the full 
impact of the integrated diabetes and kidney disease 
model of care on HRQOL. Finally, the interpretation of 
results from this study was limited by the lack of a control 
group. A randomized controlled study design although 
preferable was not feasible due to the complexity of inter-
ventions embedded within the integrated diabetes and 
kidney disease model of care.
In conclusion, this longitudinal study is the first 
to report on the impact of a codesigned, integrated 
diabetes and kidney disease model of care on HRQOL 
among patients with comorbid diabetes and CKD. We 
have shown that quality of life was maintained, and even 
improved across some subscales, among patients with 
comorbid diabetes and CKD. Integrated diabetes and 
kidney disease care may be particularly important for 
improving patient experience and clinical outcomes.
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